Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Hospira, Inc. (NYSE: HSP), the world’s leading provider of injectable drugs and infusion technologies, today reported results for the second quarter ended June 30, 2013. Net sales for the quarter were $1.0 billion and adjusted* diluted earnings per share were $0.55. (Adjusted* measures exclude certain specified items as described later in this press release and the attached schedules.) On a U.S. Generally Accepted Accounting Principles (GAAP) basis, diluted earnings per share were $0.20. Hospira, Inc. (NYSE: HSP), the world’s leading provider of injectable drugs and infusion technologies, today reported results for the second quarter ended June 30, 2013. Net sales for the quarter were $1.0 billion and adjusted* diluted earnings per share were $0.55. (Adjusted* measures exclude certain specified items as described later in this press release and the attached schedules.) On a U.S. Generally Accepted Accounting Principles (GAAP) basis, diluted earnings per share were $0.20.
